IMDX
Insight Molecular Diagnostics Inc.
Key Financials
Gross Profit
$2.3M
↑ 210.5%
Operating Income
$-51124000
↑ 16.2%
Revenue
$4.1M
↑ 115.6%
Net Income
$-50222000
↑ 17.2%
EPS (Diluted)
$-1.65
↑ 64.6%
Long-term Debt
$1.9M
N/A
Total Liabilities
$57.2M
↑ 20.8%
Shareholders' Equity
$-31464000.00
↓ 156.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-8 | 7/24/2026 | View on SEC |
| 4 | 7/6/2026 | View on SEC |
| 4 | 7/6/2026 | View on SEC |
| 4 | 7/6/2026 | View on SEC |
| 8-K | 6/17/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMDX |
| Company Name | Insight Molecular Diagnostics Inc. |
| CIK | 1642380 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | CA |
| Phone | 949-409-7600 |